-
World Cancer Day 2026: Stages Of Prostate Cancer Every Patient Must Know For Swift Medical Intervention
03 Feb 2026 06:31 GMT
… higher risk of prostate cancer. "Prostate cancer is the most … up to 10% of prostate cancers."
People living … For Prostate Cancer
People diagnosed with early prostate cancer have many … "In addition, docetaxel chemotherapy remains the first- …
-
What chemo really feels like: My prostate cancer journey
03 Feb 2026 04:41 GMT
… cocktail, in my case called docetaxel, designed to target fast-growing … ran. Men are talking about prostate cancer, asking questions, scheduling tests. That …
-
<![CDATA[Erleada Shows Survival Advantage in Real-World Study of Metastatic Prostate Cancer]]>
02 Feb 2026 19:52 GMT
… early treatment decisions in advanced prostate cancer.
Prostate cancer remains a major public health … castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through …
-
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months
02 Feb 2026 13:31 GMT
… -sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced … with metastatic castration-sensitive prostate cancer: final survival analysis … prostate-cancer-treated-with-erleada-apalutamide-versus-darolutamide-without-docetaxel …
-
Decoding GDF15’s Role in Prostate Cancer Metabolism and Therapeutic Strategies: Insights from Chinese Medical Journal
01 Feb 2026 22:28 GMT
… prostate cancer.
The challenge of chemoresistance in advanced prostate cancer … documented in docetaxel-resistant prostate cancer cell lines … low-risk prostate cancers. Additionally, … Prostate Cancer
Article Title: Decoding GDF15: Impact on prostate cancer …
-
<![CDATA[Evidence-informed management of metastatic castration-sensitive prostate cancer]]>
29 Jan 2026 15:44 GMT
… on metastatic castration-sensitive prostate cancer (mCSPC) and … and triplet approaches
Docetaxel chemotherapy remains an … to castration-resistant prostate cancer. Recognizing this shift … landscape in advanced prostate cancer management. Combination systemic …
-
<![CDATA[Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC]]>
03 Feb 2026 22:41 GMT
… ) without concurrent docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) who … Prostate Cancer Initiating Apalutamide Without Docetaxel Versus Darolutamide Without Docetaxel. Presented at: 36th International Prostate Cancer …
-
<![CDATA[Apalutamide Reduces Risk of Death by 51% in Metastatic CSPC]]>
02 Feb 2026 18:12 GMT
… docetaxel for the treatment of patients with metastatic castration-sensitive prostate cancer … prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel … metastatic castration-sensitive prostate cancer: final survival analysis …
-
Prediction of Prostate Adenocarcinoma Recurrence Prognosis and Immune Status Through 6-Acetoxy-Anopterine Resistance-Associated Programmed Cell Death Genes
30 Jan 2026 16:06 GMT
… .53 However, in prostate cancer, the tumor microenvironment … docetaxel in de novo metastatic castration-sensitive prostate cancer … of formalin-fixed prostate cancer specimens identifies biomarkers … in AE37-vaccinated prostate cancer patients reveal vaccine …
-
AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
29 Jan 2026 17:00 GMT
… docetaxel as first-line treatment of metastatic castrate refractory prostate cancer … . Cancer Stat Facts: Prostate Cancer. Available at: https:… . White paper on prostate cancer. 2020. https:… Epidemiology of Advanced Prostate Cancer and Associated Homologous …
About
© 1995-2026